Assessing the benefits and risks of amantadine for irritability and aggression after traumatic brain injury - Hammond FM, Zafonte RD, Sherer M, Bell KR, Bogner J, Malec JF, Tang Q, Jang JH.
OBJECTIVE: To quantify the benefits versus harms of amantadine in the treatment of irritability and aggression following traumatic brain injury. METHODS: Secondary outcome data from a randomized controlled multi-site trial of amantadine 100 mg twic... (Source: SafetyLit)
Source: SafetyLit - January 1, 2024 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Pharmacology in treatment of patients with disorders of consciousness - Marino MH.
Pharmacologic treatment of disorders of consciousness remains a critical but challenging task for clinicians. Amantadine has been shown to promote the rate of neurologic recovery for patients with traumatic disorders of consciousness when administered betw... (Source: SafetyLit)
Source: SafetyLit - November 24, 2023 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
Consciousness recovery in traumatic brain injury: a systematic review comparing modafinil and amantadine - Seifi A, Hassannezhad S, Mosaddeghi-Heris R, Haji Kamanaj Olia A, Adib A, Hafeez S, Barthol C.
OBJECTIVES: Acute traumatic brain injury is one of the most common causes of death and disability. Reduction in the level of consciousness is a significant complication that can impact morbidity. Glasgow Coma Scale (GCS) is the most widely used method of a... (Source: SafetyLit)
Source: SafetyLit - October 23, 2023 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
The use of amantadine in treating extrapyramidal symptoms in organophosphates poisoning in a child - Althaqafi W, Alanazi RI, Almeshari WK.
Background. Organophosphates are chemicals that lead to the accumulation of acetylcholine, causing muscarinic symptoms such as salivation and nicotinic manifestations like muscle weakness and hypertension and rarely leading to basal ganglia impairment, man... (Source: SafetyLit)
Source: SafetyLit - September 19, 2023 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
Osmolex ER (Amantadine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 23, 2022 Category: Drugs & Pharmacology Source Type: news
Strides Pharma arm gets USFDA nod to market Amantadine Hydrochloride Softgel Capsules in America
Strides Pharma Global Pte Ltd Singapore has received approval from the US Food and Drug Administration (USFDA) for the medication, the company said in a statement. The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Symmetrel Capsules, 100 mg, of Endo Pharmaceuticals, Inc (Endo). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 21, 2022 Category: Pharmaceuticals Source Type: news
Alembic Pharma gets USFDA nod for anti-viral drug
Quoting IQVIA data, Alembic Pharma said Amantadine Hydrochloride Tablets, 100 mg have an estimated market size of USD 13 million for twelve months ending June, 2020. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 16, 2020 Category: Pharmaceuticals Source Type: news
Apace Packaging LLC Issues Voluntary Nationwide Recall of Cyclobenzaprine HCL and Amantadine HCL (Lot 16710) Due to Potential Mislabeling
Apace Packaging LLC is voluntarily recalling one lot of Cyclobenzaprine HCl Tablet, USP 5 mg 50ct Unit Dose, NDC# 50268-190-15, Lot Number 16710 and one lot of Amantadine HCl Capsule, USP 100 mg 50ct Unit Dose NDC# 50268-069-15, Lot Number 16710 to the Retail level. These products have been recalled due to a potential mislabeling. A small number of cartons containing Cyclobenzaprine HCl Tablets 5 mg UD Blister Cards may potentially be mislabeled as Amantadine HCl Capsules, USP 100 mg. The unit dose blisters inside the carton are correctly labeled as Cyclobenzaprine HCl Tablet, USP 5 mg. (Source: FDA Center for Drug Evaluat...
Source: FDA Center for Drug Evaluation and Research - What's New - May 22, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
amantadine (Symmetrel - Discontinued)
Title: amantadine (Symmetrel - Discontinued)Category: MedicationsCreated: 12/14/1998 12:00:00 AMLast Editorial Review: 8/6/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 6, 2019 Category: Drugs & Pharmacology Source Type: news
Medical News Today: What are the side effects of amantadine?
This article takes a close look at the side effects of amantadine, which can range from mild to severe. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 3, 2019 Category: Consumer Health News Tags: Parkinson's Disease Source Type: news
What are the side effects of amantadine?
This article takes a close look at the side effects of amantadine, which can range from mild to severe. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - July 3, 2019 Category: Neurology Tags: Parkinson's Disease Source Type: news
Amantadine did not positively impact cognition in chronic traumatic brain injury: a multi-site, randomized, controlled trial - Hammond F, Sherer M, Malec JF, Zafonte RD, Dikmen S, Bogner JA, Bell K, Barber J, Temkin N.
Despite limited evidence to support the use of amantadine to enhance cognitive function after traumatic brain injury, the clinical use for this purpose is highly prevalent and is often based on inferred belief systems. The purpose of this study was to asse... (Source: SafetyLit)
Source: SafetyLit - May 14, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Osmolex ER (Amantadine) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 2, 2018 Category: Drugs & Pharmacology Source Type: news
FDA OKs Extended-Release Amantadine (Osmolex ER) for Parkinson's FDA OKs Extended-Release Amantadine (Osmolex ER) for Parkinson's
Osmolex ER tablets, taken once daily in the morning, are a proprietary formulation containing immediate- and extended-release amantadine.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA Approves Osmolex ER (amantadine) for the treatment of Parkinson ’s Disease and Drug-Induced Extrapyramidal Reactions
BRIDGEWATER, N.J., Feb. 19, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceutical US LLC ( “Osmotica” or the “Company”), a privately-held specialty pharmaceutical company developing novel central nervous system (CNS) treatments utilizing its... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 19, 2018 Category: Drugs & Pharmacology Source Type: news
